On September 8, C-Path and the Alpha-1 Foundation are co-hosting a virtual workshop, Shaping the Future of AATD: Patient Perspectives to Drive the Next Decade of Innovation in Alpha-1 Antitrypsin Deficiency.
Patients play a vital role in advancing research—by sharing experiences, contributing data, and advocating for earlier and better detection, therapies, and cures. That’s why your participation is essential.
If you are an AATD patient (or know someone who is), we invite you to register today and ensure the patient voice is heard. Together, we can accelerate progress for the AATD community.
The Critical Path for Alpha-1 Antitrypsin Deficiency (CPA-1) Consortium’s mission is to forge actionable, regulatory-approved drug development solutions for patients living with AATD, by working with key stakeholders in a public-private partnership dedicated to open collaboration.
The Alpha-1 Foundation is committed to finding a cure for Alpha-1 Antitrypsin Deficiency and to improving the lives of people affected by Alpha-1 worldwide.
